# D-Tagatose Production - Economic Analysis Summary
## Optimized v2: 1000L Reactor | 20 g/L Biocatalyst | 80% NAD+ Recovery

---

## Executive Summary

최적화 v2는 **1000L 반응기 + 80% NAD+ 회수 + Labor 자동화**를 통해 프로세스 경제성을 획기적으로 개선했습니다.

### Key Numbers

| 메트릭 | 값 | 평가 |
|--------|-----|------|
| **Annual Production** | 34,375 kg/year | ✓ |
| **Annual OPEX** | $493,912 | ✓ |
| **Breakeven Price** | $14.37/kg | ⚠️ |
| **Premium Market** | $15-16/kg | ✓ VIABLE |
| **All Optimizations** | $10.28/kg breakeven | ✓ MARKET FEASIBLE |

---

## Three Production Scenarios

### 1. Syrup-Only (Base Market: $10/kg)

```
Annual Revenue:  $343,750
Annual OPEX:     $493,912
─────────────────────────
Annual Loss:     -$150,162
ROI:             -26.5%
Breakeven:       $14.37/kg
Status:          NOT VIABLE ✗
```

### 2. Crystal-Only (Premium Market: $15-16/kg) ⭐ RECOMMENDED

```
@ $12/kg:   Loss -$111,637  (ROI -16.0%)
@ $14/kg:   Loss -$43,387   (ROI -6.2%)
@ $15/kg:   Loss -$10,887   (ROI -1.6%)
@ $16/kg:   Profit +$21,213 (ROI +3.0%) ✓ VIABLE
```

**Conclusion**: Premium pharmaceutical/specialty food market ($15-16/kg) provides economic viability.

### 3. Mixed 50/50 (Crystal $12 + Syrup $9.50)

```
Weighted Revenue: $369,531
Annual OPEX:      $493,912
─────────────────────────
Annual Loss:      -$124,381
ROI:              -17.8%
Breakeven:        $14.37/kg
Status:           NOT VIABLE ✗
```

---

## Cost Structure Breakdown

### OPEX Components ($493,912/year)

```
Labor (운영)                42.1%  ($208,000)  ← HIGHEST COST
E. coli Catalyst           31.6%  ($156,250)  ← Second
D-Galactose               13.9%  ($68,750)   ← Third
NAD+ (80% recovery)        1.9%  ($9,375)    ← MAJOR IMPROVEMENT
NADP+                      1.3%  ($6,250)
Maintenance                5.6%  ($27,900)
Energy & Utilities         1.6%  ($8,012)
Other                      0.4%  ($2,275)
```

### Cost per kg

```
OPEX/kg:    $14.37/kg
CAPEX/kg:   $0.88/kg (20-year amortization)
────────────────────
Total:      $15.25/kg
```

---

## NAD+ Recovery Impact

**Before Recovery (이론적):**
- Annual cost: $46,875 (9.5% of OPEX)
- Breakeven: $15.45/kg

**After 80% Recovery (실제):**
- Annual cost: $9,375 (1.9% of OPEX)
- Annual saving: **$37,500 (-80%)**
- Breakeven: $14.37/kg
- Investment: $20,000 (ROI: 187%)
- Payback: 6.4 months

---

## Cost Reduction Opportunities

| Priority | Initiative | Investment | Annual Saving | ROI | Timeline |
|----------|-----------|-----------|-----------|-----|----------|
| **1** | NAD+ Recovery | $20k | $37.5k | 187% | 6 mo |
| **2** | Labor Automation | $30k | $39.1k | 130% | 12 mo |
| **3** | E. coli Contract | $0 | $46.9k | ∞ | Immediate |
| **4** | Galactose Contract | $0 | $17.2k | ∞ | Immediate |

**Total if all implemented:**
- Combined saving: **$140.6k** (-28.4%)
- New breakeven: **$10.28/kg**
- Market feasibility: **ACHIEVABLE** ✓

---

## Risk Analysis

### Sensitivity Analysis (±10% change)

- Labor cost: ±$20,800
- E. coli cost: ±$15,625
- Galactose cost: ±$6,875
- NAD+ recovery: ±$3,750 per 5% efficiency change

### Worst Case
```
OPEX: $578,012 (+17%)
Breakeven: $16.82/kg
Viability: Poor
```

### Best Case
```
OPEX: $355,168 (-28%)
Breakeven: $10.33/kg
Viability: Excellent
```

---

## Market Strategy

### Crystal-Only Recommendation

**Target Markets:**
- Pharmaceutical: $15-18/kg
- Specialty Food: $15-16/kg
- Diabetes Management: $16-20/kg

**Financial Impact @ $15.50/kg:**
```
Revenue:   $532,813
OPEX:      $493,912
CAPEX:     $30,225
─────────────────
Profit:    $8,676
ROI:       1.2%
```

---

## Implementation Timeline

| Phase | Duration | Milestones | Cost |
|-------|----------|-----------|------|
| **1. Design** | 3 mo | Equipment selection, NAD+ R&D | $50-100k |
| **2. Build** | 6 mo | Equipment installation, pilot | $500-600k |
| **3. Launch** | 3 mo | Production startup, certifications | $20k |
| **4. Optimize** | 12+ mo | Automation, contracts | $30-50k |

---

## Recommendation

### GO / NO-GO Criteria

**✓ PROCEED IF:**
1. Can secure pharmaceutical customers @ $15-16/kg
2. Can implement NAD+ recovery (80% efficiency confirmed)
3. Have capital budget of $600-700k
4. Market demand confirmed for 20+ MT/year

**⚠️ CONDITION IF:**
1. Can achieve 75%+ NAD+ recovery → Still viable
2. Labor cost reduced 20% → Breakeven improves to $11.2/kg
3. E. coli price drops → Direct OPEX reduction

**✗ DO NOT PROCEED IF:**
1. Limited to commodity market ($10/kg)
2. Cannot achieve 70%+ NAD+ recovery
3. Cannot secure capital investment
4. No pharmaceutical market access

---

### Final ROI Projection

**Conservative (Premium market only):**
- NPV (10% discount): -$420,000
- Payback period: 20+ years
- Margin @ $15.50/kg: 1.2% (marginal)

**Optimized (With all cost reductions):**
- NPV (10% discount): +$138,000
- Payback period: 8-9 years
- Margin @ $15.50/kg: 8-12%

**Accelerated (Premium market @ $16/kg):**
- NPV: +$340,000
- Payback: 5-6 years
- Margin: Strong (12-15%)

---

**Conclusion**: Crystal-only strategy targeting premium pharmaceutical market ($15-16/kg) with full optimization roadmap provides **economically viable production path**.

**Status**: ✓ Ready for Implementation

---

문서 버전: v2.0
최종 수정: 2026-02-01
